$172 Million is the total value of Euclidean Capital LLC's 11 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -40,257 | -100.0% | -0.96% | – |
MQ | Exit | MARQETA INC | $0 | – | -247,752 | -100.0% | -2.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
ALECTOR INC | 12 | Q3 2023 | 11.5% |
RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
SURROZEN INC | 9 | Q3 2023 | 2.9% |
23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR/A | 2023-12-01 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.